The Prokinetic Cinitapride Has No Clinically Relevant Pharmacokinetic Interaction and Effect on QT during Coadministration with Ketoconazole

@article{Robert2007ThePC,
  title={The Prokinetic Cinitapride Has No Clinically Relevant Pharmacokinetic Interaction and Effect on QT during Coadministration with Ketoconazole},
  author={Marta Robert and Miquel Salv{\`a} and Rosa Segarra and Marco Pavesi and Ram{\'o}n Esbr{\'i} and D Roberts and Georg Golor},
  journal={Drug Metabolism and Disposition},
  year={2007},
  volume={35},
  pages={1149 - 1156}
}
The present clinical trial was designed to evaluate the possible pharmacokinetic and electrocardiographic interactions of the gastroenteric prokinetic drug cinitapride with ketoconazole. The safety and tolerability of the study treatments were also evaluated. After a placebo-controlled, double-blind, crossover design, 16 healthy male (n = 8) and female (n = 8) volunteers were randomized into four treatment groups of four subjects (two males and two females): cinitapride (CTP; 1 mg t.i.d… 

Tables from this paper

The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of inhaled fluticasone furoate and vilanterol trifenatate in healthy subjects.

Co-administration of FF/VI with strong CYP3A4 inhibitors has the potential to increase systemic exposure to both fluticasone furoate and vilanterol, which could lead to an increase in the potential for adverse reactions.

Pharmacokinetics and tolerability of cinitapride in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study

Good tolerability was demonstrated in both single- and multiple-dose studies with dosage range from 1 to 4 mg in healthy Chinese subjects, consistent with study results of non-Chinese subjects.

Lack of Significant Effect of Bilastine Administered at Therapeutic and Supratherapeutic Doses and Concomitantly With Ketoconazole on Ventricular Repolarization: Results of a Thorough QT Study (TQTS) With QT‐Concentration Analysis

Moxifloxacin was associated with a significant increase in QTcNi at all time points between 1 and 12 hours, inclusively, and this result was most likely related to the cardiac effect of ketoconazole.

Cinitapride Extended-Release Tablets Versus Cinitapride Immediate-Release Tablets in the Treatment of Functional Dyspepsia and Gastroesophageal Reflux Disease : A Randomized Clinical Trial

Both the study treatments were comparable in terms of safety and efficacy for the treatment of FD and GERD.

CYP2C8 *3 and *4 define CYP2C8 phenotype: An approach with the substrate cinitapride

These findings should be relevant with respect to cinitapride, but also to numerous CYP2C8 substrates such as imatinib, loperamide, montelukast, ibuprofen, paclitaxel, pioglitazone, repaglinide, or rosig litazone.

Development of an UPLC-MS/MS micromethod for quantitation of cinitapride in plasma and its application in a pharmacokinetic interaction trial.

The method proved to be rapid, accurate and stable within a range between 50 and 2000 pg/ml and was successfully validated and applied in a pharmacokinetic interaction trial, where it was demonstrated that oral co-administration of simethicone does not modify the bioavailability of CIN.

Efficacy and Safety of Cinitapride in the Treatment of Mild to Moderate Postprandial Distress Syndrome–predominant Functional Dyspepsia

This phase III trial has confirmed the noninferior efficacy of cinitapride over domperidone for patients with mild to moderate, postprandial distress syndrome–predominant FD, and its cardiovascular events need further evaluation.

Effect of axitinib on the QT interval in healthy volunteers

Since axitinib plasma concentrations observed in this study exceeded the range of concentration observed in patients with RCC at the highest approved clinical dose, axit inib was not associated with clinically significant QTc prolongation in target populations.

Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions

Current knowledge on substrates, inhibitors, inducers, and pharmacogenetics of CYP2C8, as well as its role in clinically relevant drug interactions is reviewed.

References

SHOWING 1-10 OF 39 REFERENCES

Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects.

Ketoconazole altered the pharmacokinetic profiles of both ebastine and loratadine although the effect was greater for the former drug, and changes in uncorrected QT intervals for both antihistamines were not statistically different from those observed with ketoconazoles alone.

Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects.

It is revealed that ketoconazole affected the disposition of rosiglitazone in humans, probably by the inhibition of CYP2C8 and CYP1C9, leading to increasing rosigsig litazone concentrations that could increase the efficacy ofrosig Litazone or its adverse events.

Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences.

Ketoconazole alters the metabolism of terfenadine in normal men and women and results in the accumulation of unmetabolized parent drug, which is associated with significant prolongation of the corrected QT interval and should be avoided.

Identification of the cytochrome P450 enzymes involved in the metabolism of cisapride: in vitro studies of potential co‐medication interactions

The antidepressant nefazodone, the macrolide antibiotic troleandomycin, the HIV‐1 protease inhibitors ritonavir and indinavir and the calcium channel blocker mibefradil inhibited the metabolism of cisapride and these interactions are likely to be of clinical relevance.

Cytochrome P450 2C8: Substrates, Inhibitors, Pharmacogenetics, and Clinical Relevance

A comparison of the stimulatory effects of metoclopramide and cinitapride in the guinea-pig isolated ileum.

It is concluded that cinitapride is a more potent stimulant of guinea-pig intestinal smooth muscle than metoclopramide in vitro although the mechanism of action of both drugs appears to be similar and involves a prejunctional enhancement of acetylcholine release from intramural cholinergic neurones.

Evaluation of Drug-Induced QT Interval Prolongation

Since QT interval prolongation is only an indirect surrogate of predisposition to the induction of torsade de pointes tachycardia, any conclusion that a drug is safe should be reserved until postmarketing surveillance data are reviewed, since the area of drug-related cardiac proarrhythmic toxicity is fast evolving.

Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.

The data suggest that CYP3A is the main isoform involved in the overall metabolic clearance of cisapride and that cisapride metabolism is likely to be subject to interindividual variability in CYP 3A expression and to drug interactions involving this isoform.